19 completed, 6 recruiting, 4 withdrawn, 2 terminated. 9 Phase 2, 8 Phase 1, 6 Not applicable, 6 Phase 3, 5 Phase 4.
Follow Fludrocortisone: new trials by email Literature Review of Fludrocortisone trials Research Report on Fludrocortisone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial Tocilizumab, Baricitinib, Anakinra - Sepsis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2000 | 2026-07-09 | 2026-10-20 |
| Adjunctive Fludrocortisone in Septic Shock Fludrocortisone 100 mcg daily, Placebo - Sepsis, Septic Shock | Phase 2 | Recruiting | Chinese University of Hong Kong | 32 | 2026-04-01 | 2026-06-02 |
| Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock Hydrocortisone plus Fludrocortisone, Standard care - Septic Shock | Phase 4 | Recruiting | Northern Jiangsu People's Hospital | 336 | 2026-03-02 | 2026-03-04 |
| FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage Fludrocortisone, Placebo - Aneurysmal Subarachnoid Hemorrhage | Phase 2 | Recruiting | The George Institute | 524 | 2025-08-13 | 2025-12-16 |
| Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery hydrocortisone plus fludrocortisone, placebo of hydrocortisone plus fludrocortisone - Inflammation in Cardiac Surgery | Phase 3 | Recruiting | Centre Hospitalier Universitaire, Amiens | 196 | 2025-04-30 | 2026-06-03 |
| A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) [¹⁴C]Opevesostat, Prednisone, Fludrocortisone - Metastatic Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 8 | 2024-09-19 | 2024-10-23 |
| Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects Vamorolone, Eplerenone, Fludrocortisone - Pharmacodynamic | Phase 1 | Completed | Santhera Pharmaceuticals | 30 | 2024-06-05 | 2025-09-11 |
| A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) Opevesostat, Dexamethasone, Fludrocortisone - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2024-01-30 | 2026-03-19 |
| Platform of Randomized Adaptive Clinical Trials in Critical Illness Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL) - Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication | Not applicable | Recruiting | University Health Network, Toronto | 6250 | 2023-04-30 | 2026-10-22 |
| Androgen Reduction in Congenital Adrenal Hyperplasia Abiraterone acetate, Placebo, Hydrocortisone - Congenital Adrenal Hyperplasia | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2023-01-01 | 2023-02-01 | |
| Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients Fludrocortisone, Placebo - Septic Shock | Phase 2 / Phase 3 | Suspended | Rennes University Hospital | 40 | 2022-03-31 | 2023-11-18 |
| Stress & Social Cognition in BPD (part 2) Fludrocortisone, Placebo, Trier Social Stress Test (TSST) - Borderline Personality Disorder | Not applicable | Completed | Charite University, Berlin, Germany | 240 | 2022-02-01 | 2025-03-06 |
| Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension Fludrocortisone, Placebo - Neurogenic Orthostatic Hypotension | Phase 4 | Unknown | H.A.C. PHARMA | 90 | 2020-07-09 | 2023-10-02 |
| Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults Hydrocortisone - Septic Shock | Phase 4 | Completed | Ain Shams University | 66 | 2018-09-01 | 2020-07-30 |
| Impact of the Administration of Fludrocortisone in Very Premature Infants Oral Fludrocortisone (enteral), Placebo Oral Tablet - Partial Mineralocorticoid Deficiency | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 66 | 2017-06-01 | 2021-02-16 |
| Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression Placebo, Fludrocortisone, D-Cycloserine - Major Depression | Not applicable | Completed | Charite University, Berlin, Germany | 232 | 2016-09-27 | 2020-06-23 |
| The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production Placebo, Fludrocortisone, Eplerenone - Healthy Volunteers | Phase 1 | Completed | Brigham and Women's Hospital | 23 | 2016-01-01 | 2021-06-08 |
| A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects AZD9977 oral suspension, AZD9977 placebo oral suspension, Fludrocortisone, tablets - Pharmacodynamics, Healthy Subjects | Phase 1 | Completed | AstraZeneca | 40 | 2015-09-01 | 2017-03-29 |
| Effects of Mineralocorticoid Receptor Stimulation on Cognition Fludrocortisone - Individuality | Not applicable | Completed | Charite University, Berlin, Germany | 80 | 2015-05-01 | 2016-03-07 |
| Fludrocortisone in Healthy Volunteers (AFLUCO4) Fludrocortisone 100 μg, Fludrocortisone 200 μg, Fludrocortisone 400 μg - Healthy Volunteers | Phase 2 | Completed | Rennes University Hospital | 16 | 2014-07-01 | 2018-08-29 |
Showing 20 of 34. Sign in to see all of them.
Shock, Septic (7) · Sepsis (3) · Adrenal Hyperplasia, Congenital (2) · Adrenal Insufficiency (2) · Depressive Disorder, Major (2) · Prostatic Neoplasms (2) · Acidosis, Renal Tubular (1) · Borderline Personality Disorder (1) · Depression (1) · Diabetes Mellitus, Type 1 (1) · Hearing Loss (1) · Hearing Loss, Sensorineural (1) · Hypertension (1) · Hypoglycemia (1) · Hypotension, Orthostatic (1)
Rennes University Hospital (4) · Charite University, Berlin, Germany (3) · Assistance Publique - Hôpitaux de Paris (2) · Merck Sharp & Dohme LLC (2) · University of Versailles (2) · Ain Shams University (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · CAMC Health System (1) · Centre Hospitalier Universitaire, Amiens (1) · Chinese University of Hong Kong (1) · Christian Baumann (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Fundação de Amparo à Pesquisa do Estado de São Paulo (1) · H.A.C. PHARMA (1)
France (10) · Germany (5) · United States (5) · Australia (3) · China (2) · Hong Kong (2) · New Zealand (2) · Switzerland (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Colombia (1) · Egypt (1) · Italy (1) · Netherlands (1)
Christian Otte, MD (2) · Alain Cariou, MD (1) · Alex Nesbitt, MBBS (1) · Anastasia Newman, PhD (1) · Andrea Castellvi Font, MD, PhD (1) · Andrew Turner, MBBS (1) · Andrew Udy, BHB MB ChB (1) · Anh Nguyen-Huynh, MD PhD (1) · Anthony Delaney, MBBS (1) · Benoit Misset, MD (1) · Bijan Teja, MD (1) · Bram Rochwerg, MD, MSc (1)
PMID 10321661, PMID 10697064, PMID 10923728, PMID 12186604, PMID 20103758, PMID 23525934, PMID 28224720, PMID 29490185, PMID 3029157, PMID 30581606, PMID 32722659, PMID 3306374, PMID 34000076, PMID 38310918, PMID 39672600, PMID 40677678, PMID 40957504, PMID 4101232, PMID 42581762, PMID 42800510, PMID 6270176, PMID 6384785, PMID 7600840, PMID 7634816, PMID 7638758, PMID 8815944, PMID 8855809, PMID 9559600
2014 (1), 2015 (1), 2018 (1), R01DK069803 (1)